SK bioscience and Australia’s Peter Doherty Institute for Infection and Immunity have signed a research collaboration deal for the development of a next-generation influenza vaccine.
The company and the research institute will collaborate in further research on influenza biology, antivirals and vaccines.
The programme will include testing anti-influenza compounds to identify new antivirals, a new influenza vaccine platform development and building vaccine capacity in low and middle-income countries.
SK bioscience CEO Jaeyong Ahn said: “We expect a synergy combined with our capability in developing the world´s first quadrivalent cell culture-based influenza vaccine and the infrastructure of the Doherty Institute, a leading research institution on global infectious diseases.
“We will strengthen global partnerships with various organisations and continuously expand cooperative areas to establish a response system against infectious disease pandemics in the world.”
The company also intends to establish a proactive response system against influenza, contributing to public health on a global scale.
Doherty Institute director Professor Sharon Lewin stated: “Our organisations joining forces through our influenza projects is a significant milestone in our shared commitment to tackling infectious diseases and promoting public health.
“By collaborating with SK bioscience, we will strengthen our ability to respond to global challenges through exchanging knowledge and fostering innovation.
“Together, we will make a lasting impact in the prevention and treatment of infectious diseases, like influenza, around the world.”
Source link
#bioscience #Doherty #Institute #partner #influenza #vaccine
